Repare Therapeutics Inc. (NASDAQ:RPTX) shares traded higher over the last trading session, gaining 1.00% on 05/20/21. The shares fell to a low of $34.11 before closing at $34.47. Intraday shares traded counted 0.5 million, which was -242.87% lower than its 30-day average trading volume of 145.97K. RPTX’s previous close was $34.13 while the outstanding shares total 36.92M. The stock’s Relative Strength Index (RSI) is 61.50, with weekly volatility at 5.80% and ATR at 1.73. The RPTX stock’s 52-week price range has touched low of $21.45 and a $46.44 high.
Investors have identified the Biotechnology company Repare Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.23 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Repare Therapeutics Inc. (RPTX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 328.21 million total, with 12.42 million as their total liabilities.
RPTX were able to record -15.0 million as free cash flow during the 08/19/2021 quarter of the year, this saw their quarterly net cash flow reduce by -14.78 million. In cash movements, the company had a total of -14.23 million as operating cash flow.
Potential earnings growth for Repare Therapeutics Inc. (RPTX)
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 0.17 million trying to sell their products during the last quarter, with the result yielding a gross income of 21.75 million. This allows shareholders to hold on to 36.92M with the recently reported earning now reading -0.58 cents per share. This is a figure that compared to analyst’s prediction for their 08/19/2021 (-0.58 cents a share).
Having a look at the company’s valuation, the company is expected to record -2.79 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on RPTX sounds very interesting.
Is the stock of RPTX attractive?
In related news, Director, Foley Todd sold 4,387 shares of the company’s stock in a transaction that recorded on May 20. The sale was performed at an average price of 34.69, for a total value of 152,194. As the sale deal closes, the 10% Owner, GADICKE ANSBERT now sold 9,957 shares of the company’s stock, valued at 345,428. Also, 10% Owner, GADICKE ANSBERT sold 13,543 shares of the company’s stock in a deal that was recorded on May 19. The shares were price at an average price of 34.48 per share, with a total market value of 466,965. Following this completion of acquisition, the President and CEO, Segal Lloyd Mitchell now holds 3,800 shares of the company’s stock, valued at 133,228. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.20%.
6 out of 7 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on Repare Therapeutics Inc.. 0 analysts has assigned a Sell rating on the RPTX stock. The 12-month mean consensus price target for the company’s shares has been set at $46.50.